ASCO GU 2024

Is "more" always better?

Combination vs. monotherapy - a great new option for high-risk patients

BRCAAway - practice changing or hypothesis generating data?

Cabo + IO: Interesting but not practice changing?!

Still a difficult time for androgenic inhibitors in mCRPC

Localized PCa - news for radiotherapy and biochemical recurrence

Long-term dose escalation - Therapy in high-risk prostate cancers

Quality of life under intensive therapy

First positive study of IO therapy in mCRPC

Further testing before olaparib combination

BRCAaway - PARP combination study

Olaparib + Arbiraterone better compared to either alone

What about the clinical benefit?

Stockholm3 validated in multiethnic cohort

Enzalutamide therapy as option for biochemical recurrence

Therapy Intensification Still Neglected in mHSPC

Insights and news for mCRPC

Dose de-escalation in different ways

Relugolix combined with androgen signaling in real word experience

Salvage radiation with anti-androgen superior to radiation alone

Combination of cabozantinib & checkpoint inhibitor

Higher radiation is effective in high-risk PCA

Cognitive function in ART treatment

Gleason 3+3 - cancer or not?

Combination NHT + PARP makes sense

Evaluating the recombination-repair mutations in patients with mCRPC

Gleason 3+3 ska vi kalla de cancer eller inte?

Kombination av cabozantinib och immunterapi

Kognitiv påverkan av abirateron och enzalutamid?

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

BRCAAway - PARP hämmare, abiraterone eller i kombination

The emerging field of biomarkers in bladder cancer

New standard of care, but still open questions!

ADC + ICI: new data for platinum-refractory bladder cancaer patients

Advances in (neo)-adjuvant treatment in urothelial cancer

EV + Pembro new first-line standard in localized metastatic bladder cancer

Biomarker update

MIBC: adjuvant PD1 - all set?!

Another success for an ICI?

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Update on EV-302

Pembrolizumab adjuvant in bladder cancer

Highlights in bladder cancer at ASCO GU24

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

EV as standard in 3rd line mUC

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Perioperative adjuvant therapy in urothelial cancer

Update M1 urothelial cancer

HER2 and bladder cancer

ASCO GU24 - Highlights in Bladder cancer

Terapia adyuvante perioperatoria en el cáncer de vejiga

Encore un succès pour une ICI ?

Novedades sobre EV-302

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Subcutaneous vs. intravenous application: ready for everyday clinics?

No surprise with the QoL data

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Belzutifan: Updates on QoL

Overall survival benefit - Pembro after surgery

ASCO GU24 - Highlights in renal cell carcinoma

Tumorburden and outcome

Better QoL with Belzutifan

Long-Term Data on NIVO+IPI in aRCC

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

Highlights in kidney cancer at ASCO GU24

Practice changing adjuvant therapy?!

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Long-term outcome

Perioperative treatment in renal cell carcinoma - did we close the circle?

Durable effects of Ipi-Nivo

Long-term follow-up of first-line trials

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?